Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleDo cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
Author(s)Wade DT, Makela P, Robson P, House H, Bateman C.
Journal, Volume, IssueMultiple Sclerosis 2004;10(4):434-41.
Major outcome(s)Spasticity scores were significantly reduced by cannabis.
IndicationSpasticity;Multiple sclerosis;Pain;TremorAbstract

The objective was to determine whether a cannabis-based medicinal extract (CBME)
benefits a range of symptoms due to multiple sclerosis (MS). A parallel group,
double-blind, randomized, placebo-controlled study was undertaken in three
centres, recruiting 160 outpatients with MS experiencing significant problems
from at least one of the following: spasticity, spasms, bladder problems, tremor
or pain. The interventions were oromucosal sprays of matched placebo, or whole
plant CBME containing equal amounts of delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD) at a dose of 2.5-120 mg of each daily, in divided doses. The
primary outcome measure was a Visual Analogue Scale (VAS) score for each
patient's most troublesome symptom. Additional measures included VAS scores of
other symptoms, and measures of disability, cognition, mood, sleep and fatigue.
Following CBME the primary symptom score reduced from mean (SE) 74.36 (11.1) to
48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following
placebo [ns]. Spasticity VAS scores were significantly reduced by CBME (Sativex)
in comparison with placebo (P =0.001). There were no significant adverse effects
on cognition or mood and intoxication was generally mild.

Dose(s)2.5-120 mg THC and CBD
Duration (days)
Participants160 patients with MS
DesignControlled study
Type of publicationMedical journal
Address of author(s)Oxford Centre for Enablement, Windmill Road, Oxford OX3 7LD, UK.
Full text

[Back to Overview]  [IACM Homepage]